24 October 2019: Laboratory Research
Exosome-Mediated MiR-155 Transfer Contributes to Hepatocellular Carcinoma Cell Proliferation by Targeting PTEN
Jing-Feng Sun BE 1, Dong Zhang CD 2, Cai-Jie Gao F 3, Ye-Wei Zhang AG 1*, Qing-Song Dai A 4
DOI: 10.12659/MSMBR.918134
Med Sci Monit Basic Res 2019; 25:218-228
Abstract
BACKGROUND: Most eukaryocytes release nano vesicles (30–120 nm), named exosomes, to various biological fluids such as blood, lymph, and milk. Hepatocellular carcinoma (HCC) is one of the tumors with the highest incidence rate in primary malignant carcinoma of the liver. However, the mechanism of HCC proliferation remains elusive. In this study, we aim to explore whether HCC cell-derived exosomes affect the proliferation of cancer cells.
MATERIAL AND METHODS: Exosomes were isolated from HCC cells by ultracentrifugation and were visualized the phenotype by transmission electron microscopy. Cell proliferation was detected by Cell Counting Kit-8 assays and EdU (5-ethynyl-2-deoxyuridine) incorporation assays. Dual-luciferase assays were performed to validate the paired correlation of miR-155 and 3’-UTR of PTEN (gene of phosphate and tension homology deleted on chromosome 10). A xenograft mice model was constructed to verify the effect of exosome-mediated miR-155 on cell proliferation in vivo.
RESULTS: Our finding showed that miR-155 was enriched in exosomes released from HCC cells. The exosome-containing miR-155 transferred into new HCC targeted cells and lead to the elevation of HCC cells’ proliferation. Besides, the exosomal miR-155 directly bound to 3’-UTR of PTEN leading to the reduction of relevant targets in recipient liver cells. The knockdown of PTEN attenuated the proliferation of HCC cells treated with the exosomal miR-155. Moreover, nude-mouse experiment results revealed a promotional effect of the exosomal miR-155 on HCC cell-acquired xenografts.
CONCLUSIONS: Our study indicated that exosomal-specific miR-155 transfers to adjacent and/or more distant cells and stimulates the proliferation of HCC cells.
Keywords: Carcinoma, Hepatocellular, exosomes, Liver Neoplasms, Microscopy, Electron, Transmission
Background
Hepatocellular carcinoma (HCC) is the highest incidence type of primary hepatic malignancy cancer and occurs mainly in people with hepatitis B and C and cirrhosis. HCC is the 3rd most high cause of cancer deaths all over the world, leading to over 500 000 people affected, particular in developing countries due to late diagnosis and poor treatment options [1–4]. However, the pathogenesis of HCC is still far from clear. The discovery of a type of highly conserved small non-coding RNAs with pleiotropic regulatory functions, microRNA (miRNA), has a significant contribution to the deep molecular understanding of hepatocarcinogenesis [5,6]. Owing to the short sequence requirement for incomplete complementarity, an independent miRNA has the capacity to modulate hundreds of targeted genes. It is widely accepted that miRNAs potentially regulate many aspects of tumorigenesis, including proliferation and development, differentiation metabolism, and apoptosis [6–10]. For instance, miR-194 targets
Exosomes are nanometer-sized (30–120 nm) membrane vesicles that are secreted from almost all cells, including cancer cells. Ever-increasing studies confirm that proteins, mRNA, and non-coding RNA participate in all biological processes of malignant carcinoma [13–15]. Remarkably, cancer-released exosomes make up a network of the exchange between tumors and non-carcinoma tissues. The evolution of exosome-associated tumor depends on the external stroma of cancer, such as affecting metastasis and development [16–18]. Fu et al. demonstrated that attachment to HCC cell-released exosomes contain SMAD3 protein and stimulate the dispersion of HCC cells [19]. MiR-18a reduces the expression of estrogen receptor-α to promote HCC proliferation and development in women [20].
Exosomal RNAs are released into recipient cells and regulate their biological functions [21]. RNA sequencing (RNA-seq) has shown that miRNAs are abundant in exosomes [22]. In the current study, we discovered that miR-155 was preferentially enriched in exosomes that released from HCC cells.
Material and Methods
CELL CULTURE:
We purchased HCC cell lines (MHCC97H, SMMC7721, Hep3B, and HepG2) and human immortalized normal hepatocyte cell line (LO2) from American Type Culture Collection. All cell lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Hyclone, MA, USA) containing 10% fetal bovine serum (FBS), with 100 U/mL penicillin, 100 μg/mL streptomycin (Hyclone, USA) in a 5% CO2 incubator at 37°C.
EXOSOME ISOLATION:
The cells were cultured in a medium supplemented with 2% exosome depleted FBS (SBI, USA). Centrifuge cultural supernatants for 10 minutes at 1500 g to remove dead cells. After discarding the pellet, the supernatant was transferred to a new collection tube. Then the supernatant was ultra-centrifuged at 12 000 g for 30 minutes (Beckman Coulter Optima MAX-XP), and exosomes were pelleted by ultracentrifugation at 100 000 g for 70 minutes. After discarding the supernatant, the exosome pellet was re-suspended in phosphate-buffered saline (PBS) and centrifuged at 100 000 g for 70 hours.
TRANSMISSION ELECTRON MICROSCOPY:
An equal volume of 4% paraformaldehyde was added to the exosome sample and incubated for 2 hours. Then 3 μL aliquots of exosomes were dropped onto the grids which were then incubated in 2% paraformaldehyde for 20 minutes. The grids were transferred to a wax strip and washed with 100 mL PBS. The grids were incubated in 50 mM glycine/PBS for 5 minutes and blocked in 5% bovine serum albumin (BSA)/PBS for 10 minutes and washed with PBS followed by incubation in 2.5% glutaraldehyde for 5 minutes. Following washes of 2 minutes with H2O, the grids were incubated for 5 minutes in uranyl oxalate and in 1% methyl cellulose. Excess liquid was removed with a filter paper, and the grids were air-dried for 30 minutes. Exosomes were visualized under a Hitachi 7000 transmission electron microscope (Hitachi, Tokyo, Japan) operated at 120 kV.
CELL COUNTING KIT-8 (CCK-8) ASSAY:
We measured cell proliferation using the Cell Counting Kit-8 (CCK-8) assay kit (Dojindo, Japan). Dispense 100 μL of cell suspension (5000 cells/well) in a 96-well plate. The plates were pre-incubated for 24 hours in a humidified incubator (37°C, 5% CO2). Then 10 μL of different concentrations of the test substance were added to the plate. Incubate the plate for an appropriate time in the incubator. Add 10 μL of CCK-8 solution to each well of the plate. The plates were incubated for 1 hour in an incubator. Measure the absorbance at 450 nm using a microplate reader (Bio-Tek, Elx800, USA).
GENERATION OF MIR-155 KNOCKOUT CELLS LINE:
The lentiviral packaging plasmid pMD2.G (Addgene 12259), psPAX2 (Addgene 12260), and lenti-CRISPRv2 (Addgene 52961) were obtained from Addgene. The gRNA targeting miR-155 genomic sequence was sub-cloned into the lenti-CRISPRv2 vector. The gRNA sequence (5′-GTTAATGCTAATCGTGATAG-3′) was designed online (
EDU INCORPORATION ASSAY:
The 5-ethynyl-2-deoxyuridine (EdU) incorporation assay was measured as previously described using the Click-iT®EdU [23].
NANOPARTICLE TRACKING ANALYSIS:
Exosomes particles, using nanoparticle tracking analysis (NTA), were measured as previously described [24].
WESTERN BLOTTING:
Western blotting was used to analyze protein expression according to standard procedures. After various treatments, exosomes fraction or HCC cells were lysed with radioimmunoprecipitation assay (RIPA) buffer (Santa Cruz, LA, USA).The isolated total protein was separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred onto polyvinylidene difluoride (PVDF) membranes (Millipore, USA). Blocked with 5% non-fat dried milk, the membranes were subsequently incubated with appropriate primary and secondary antibodies and washed. The membranes were imagined using Li-COR Odyssey Infrared Imager (Li-COR Bioscience). The primary antibodies used were CD63 (Santa Cruz), TSG101 (Proteintech), PTEN, Akt, p-Akt, and GAPDH (all from Abcam).
RNA PREPARATION AND QUANTITATIVE REAL-TIME PCR:
Total RNA was isolated from HCC cells after treatment by using TRIzol reagent (TaKaRa) and operated strictly according to the manufacturer’s instructions. Reverse transcription was performed on 2.0 μg of total RNA from each sample using the First Strand cDNA Synthesis Kit (TaKaRa). We performed quantitative real-time (RT)-PCR reaction by using SYBR Green Master Mix (Life Technologies). Quantitative PCR was performed with the ABI Step OnePlus™ system (Applied Biosystems). We purchased RT and PCR primers for miR-155 and U6 from RiBoBio (Guangzhou, China). All miRNA quantification data were normalized U6 snRNA. The Data were analyzed using2−ΔΔCt method.
LUCIFERASE ASSAYS:
We used the dual-luciferase reporter assay system (Promega, USA) to detect firefly and Renilla luciferase activity. The
:
Animal experimental protocols were approved by the Animal Experimentation Ethics Committee of Nanjing Medical University. As regard tumor growth analysis in a xenograft model, 5-week-old male nude mice (BALB/c nu/nu) were from the Model Animal Research Center of Nanjing University (Nanjing, China) under specific pathogen-free conditions. We injected HepG2 cells (2×106) subcutaneously into the posterior side of each mouse. Once the tumors formed after 15 days, 100 ug exosomes were injected into each tumor. After 15 days, mice were sacrificed, and tumors weight was measured.
IMMUNOHISTOCHEMISTRY:
The slides were heated for 15 minutes and subjected to antigen retrieval with citrate buffer (pH 6.0) after deparaffinization and rehydration. After blocking, sections were incubated overnight at 4ºC with the PTEN antibodies (Abcam). Two-step technique (SuperPicture™ 3rd Gen IHC Detection kit; Invitrogen, CA, USA) was used for visualization, with diaminobenzidine as a chromogen. In the end, the sections were counterstained with hematoxylin and mounted. We considered immunostaining was apparent in the nucleus as positive PTEN expression.
STATISTICAL ANALYSIS:
Data from at least 3 independent experiments was analyzed using the GraphPad Prism program (version 7.00 for Windows, San Diego, CA, USA). All data were expressed as mean±standard error of mean (SEM) and analyzed with Student’s
Results
PROFILES OF EXOSOMAL MIRNAS THAT ARE UPREGULATED IN HCC VIA MEASURING THE SERIES OF RNA:
We utilized the sequencing of RNA to explore the enrichment level of microRNA (miRNA) in exosomes which release from HCC cells. To compare the exosomal RNA profiles that derived from HCC cells or normal hepatic cells, exosomes were isolated from the cultural clear liquid on the surface of MHCC97H (an HCC cell line), as well as LO2 (the people’s immortalized hepatocyte line) as a control. Using transmission electron microscope (TEM) the sizes of the extracellular vesicles were predominantly in almost 100 nm in the radius of the isolated exosomes fraction (Figure 1A). This data was consistent with the nanoparticle tracking analysis (NTA); NTA showed the peak size of 100 nm (Figure 1B). Moreover, the features of isolated exosomes were identified by western blotting through detecting special exosomal protein CD63 and TSG101, which was consistent with commercial exosome-standard samples (Exo standard) (Figure 1C). The data demonstrated that the isolated exosomes were in line with the size and morphology reported as before. Compared with LO2 cells, 36 miRNAs were significantly gathered in exosomes released from MHCC97H cells (Figure 1D). For miRNAs in exosomes, we were concerned about miR-155 presenting the highest expression in exosomes (Figure 1D). Quantitative detection by RT-PCR was used to determine RNA sequencing result and found the enrichment level of miR-155 in exosomes of other HCC cells lines. The expression of miR-155 in Hep3B, HepG2, and SMMC7721 HCC cell lines derived exosomes was higher than that in LO2 cells (Figure 1E). These results showed that miR-155 was enriched in exosomes from HCC cells.
THE EXOSOMAL MIR-155 PROMOTED HCC CELL PROLIFERATION:
To explore whether exosomal miR-155 has functional effects on HCC cell proliferation, we constructed a miR-155 gene-knockout Hep3B cell line (Hep3B-miR-155-KO) through the Clustered Regulatory Interspaced Short Palindromic Repeat-cas9 (CRISPR-CAS9) method. MiR-155 was deleted in Hep3B cells (Figure 2A). We collected the exosomes from the cell culture of Hep3B cells (Exo-WT) as well as Hep3B-miR-155-KO cell (Exo-miR-155-KO) to incubate HepG2 cells for 24 hours (Figure 2B). The proliferation ability of HepG2 cells was significantly weaker in Exo-miR-155-KO treatment group than that in Exo-WT incubated group by CCK-8 assay (Figure 2C). Because the most accurate method for testing cell growth is the direct measurement of DNA synthesis, we chose the 5-ethynyl-2′-deoxyuridine (EdU) assay to confirm the proliferation ability of HCC cells. The proliferation ability of HepG2 cells showed a significantly elevation when incubated with Exo-miR-155-KO reference to the treatment group with Exo-WT (Figure 2D). This result indicated that miR-155 has a potential ability of affecting HCC proliferation. At the same time, we co-cultured the Hep3B or Hep3B-miR-155-KO cells with HepG2 cells for 24 hours in a Transwell system. A higher OD450 value of HepG2 cells co-cultured with Hep3B-HepG2 than that of miR-155-KO-HepG2 co-culture system (Figure 2E), suggesting that the soluble factors from Hep3B cells facilitated the proliferation of HepG2 cells. Together, these observations indicated that exosomal miR-155 is transported to a new HCC cells to promote the proliferation.
:
To explore the molecular mechanism underlying the biological effects of exosomal miR-155 to promote HCC cell proliferation, we analyzed the potential miR-155 target genes by the miRNA online target databases (miRDB, TargetScan, multiMiR, and miRNA.org). Then we analyzed the RNA structure and calculated the scores of each feature to predict the most effectively targeted mRNAs. Among these predicted target genes, we focus on PTEN gene, which was predicted by all above miRNA database. PTEN is known to play as a tumor suppressor which dephosphorylates PIP3 produced by phosphatidylinositol-3-kinase (PI3K) to regulate cell biological processes including proliferation [25–28]. Moreover, PTEN was downregulated in rat HCC model and HCC tissue specimens as previous report [29]. To explore whether that miR-155-containing exosome carried into other cells caused a decrease of the predicted target gene, the PTEN 3′-UTRs were linked into luciferase-reporter plasmids (Figure 3A). HepG2 cells were transfected with PTEN 3′-UTRs luciferase-reporter plasmids and then incubated with Exo-WT or Exo-miR-155-KO. The reporter assays indicated that Exo-WT significantly decreased the relative luciferase ability of the reporter construct containing wild-type PTEN 3′-UTR in HepG-2 cells, while the luciferase ratio of the mutational PTEN 3′-UTR reporter vector had no change (Figure 3B). These results indicated the predicted miR-155 targeted sites in the PTEN 3′UTRs were essential for exosomal miR-155-mediated suppression.
Meaningfully, the Exo-miR-155-KO treatment had no effect on the relative luciferase ability to wild-type receptor or mutational PTEN 3′-UTR. Furthermore, the transfer of Exo-WT decreased the expression of target PTEN proteins in recipient HepG2 cells using western blotting, while Exo-miR-155-KO treatment showed no significant changes in PTEN expression (Figure 3C). Because PTEN plays a major negative role on PI3K-Akt pathway [30], we explored the function of the exosome-laden miR-155 on PI3K-Akt pathway. We found the phosphorylated-Akt (p-Akt) were dramatically decreased in Exo-WT treatment group compared with that in NC or Exo-miR-155-KO treatment group (Figure 3C). Our results concluded that exosomal miR-155 contributed to directly inhibit PTEN expression and activated the PI3K-Akt pathway.
EXOSOMAL MIR-155 PROMOTES THE PROLIFERATION OF HCC CELLS THROUGH PTEN:
To validate the function of PTEN on the growth of HCC, we investigated the miRNA-155 effects on differentiation of HCC cells according to PTEN expression knockdown using lentivirus shRNA-PTEN vectors. Western blotting demonstrated that PETN was significantly knockdown in HepG2 cells, suggesting the stable PTEN-KD HepG2 cells was successfully constructed (Figure 4A). Then, we treated HepG2 PTEN-KD cells with an equal quality of Exo-WT as well as Exo-miR-155-KO for 24 hours. The proliferation of HepG2 PTEN-KD cells had no significant difference between Exo-WT and Exo-miR-155-KO treatment using CCK-8 assay and EdU staining (Figure 4B, 4C). These results demonstrated that PTEN functions as a crucial function in the differentiation of HCC cells induced via exosome-laden miRNA-155.
:
To confirm the proliferation ability of miR-155 in HCC tumor formation, we injected HepG2 cells subcutaneously into nude mice to form tumor masses. After 15 days, the mouse with the tumor mass was injected with an equal protein quality Exo-WT or Exo-miR-155-KO to assess whether exosome-laden miR-155 had effect on HCC cell tumor formation in vivo (Figure 5A). As shown in Figure 5B, the volume of tumors grew obviously faster when injected with Exo-WT from 7 days with 490 mm3 than Exo-miR-155-KO-injected group with 445 mm3. The tumor weight from Exo-WT injection were significantly higher than Exo-miR-155-KO-injected group, with average of 1.654 g in Exo-WT group and 0.8926 g in Exo-miR-155-KO-group (Figure 5C). Moreover, the PTEN antigen staining density in Exo-WT-injected tumor tissue was decreased compared to the Exo-miR-155-KO-injected tumor by immunohistochemistry analysis (Figure 5D). Thus, we provide evidence that exosomal miR-155 promotes HCC growth through targeting PTEN in animal experiment.
Discussion
In most countries, the high mortality rate of HCC is almost equal to the incidence of HCC, indicating the lack of effective therapies for HCC [2,31]. Many studies have shown that DNAs, exosome proteins and RNA, make contributions to the development of HCC [3,17,18]. MiRNAs package in exosomes should be shift to neighboring recipient and then exert the regulation of target genes [16,21,32]. Therefore, miRNAs in cancer-secreted exosomes play a critical role in controlling internal environment around the tumor and lead to the uncontrollable growth of tumor. However, the function and mechanism of HCC-derived exosomes have not been well established. In our study, we aimed to validate whether exosomes released from HCC cells regulate the proliferation of HCC cells. Our finding showed that miR-155 was expressed in exosomes that are released from HCC lines. Then, we found that the exosome-containing miR-155 was taken up by targeted cell, which promoted the cell proliferation of liver carcinoma. Further study demonstrated that the exosome-laden miR-155 directly targeted the
The miR-155 is located in 21q21.3 of human chromosome and is originally defined as an insertion site of the Poultry leukocyte virus [33–35]. The previous study demonstrated that miR-155 was increased in primary liver cancer specimens and in the early stages of hepatocarcinogenesis [36]. MiR-155 is considered to be predictive as a poor survival marker in liver transplantation [37]. Several studies have indicated that miR-155 plays an importance on positive neoplastic epithelial adhesion molecules of HCC [38]. Nowadays, miR-155 has been confirmed to participate in immune system response, cardiovascular diseases, and tumorigenesis [33,34,37]. However, the mechanisms of exosomal miR-155 of HCC development has not been explored. In our study, we showed that miR-155 was preferentially enriched in exosomes that released from HCC lines.
Because the exosomal miRNAs can be carried into neighboring cells or distant cells and lead to the modulation of recipient cells, we constructed a miR-155-KO Hep3B cell line to confirm whether exosome-laden miR-155 has functional effects on HCC cell proliferation. Exosomes from wild-type Hep3B were enriched with miR-155 according to the RNA-Seq data and RT-PCR analysis. The exosomes release from miR-155-KO Hep3B cells were lacking miR-155. Using the KO cells model, we found that the exosome-containing miR-155 from wild-type Hep3B cells was transferred into HepG2 cells and promoted the cell proliferation.
Generally, the miRNA regulates the expression of hepatocellular carcinoma genes via the 3′-UTR region of targeted mRNAs at the post-transcriptional level to inhibit translation and/or induce mRNAs degradation [9]. To explore the biological mechanisms of miR-155 on cell proliferation of HCC, we utilized the miRNA prediction databases to analyze the potential target genes. PTEN is a dominant cancer-suppressor gene blocking PI3K-Akt pathway via PIP3. Emerging evidence revealed PTEN deficiency, mutation or inexpression has been discovered in a lot of malignant tumors, such as the liver, breast, lung, brain, and prostate cancers [25,39–44]. Our findings showed that the exosome-laden miR-155 directly targeted
More and more evidence has demonstrated that the exosome-associated miRNAs are defined as novel biological biomarkers in HCC. Previous studies have shown that miR-122, miR-1246, and miR-148a in serum exosomes in HCC were significantly higher than hepatitis C and healthy liver samples [45]. Fornari et al. showed that HCC-released exosomes, which contained miR-21, miR-221, miR-519d, and miR-1228 were correlated with circulating and tissue levels [46]. Lin et al. examined the miR-210 released from HCC stimulates cancer angiogenesis by blocking the entry of SMAD4 and STAT6 into vascular endothelial [47]. Corresponding to the results of our study, Matsuura et al. confirmed that HCC-related miR-155 was upregulated in hypoxic environment, resulting in the tube formation of HUVECs [48]. Our studies suggested that exosomal miR-155 could promote HCC cell proliferation and trigger the PI3K-Akt pathway activity by targeting PTEN
Conclusions
Our investigations suggest that exosomal miR-155 promotes HCC cell proliferation and triggers the PI3K-Akt pathway activity by suppressing PTEN
References
1. Coskun M, Hepatocellular carcinoma in the cirrhotic liver: Evaluation using computed tomography and magnetic resonance imaging: Exp Clin Transplant, 2017; 15; 36-44, pmid: 28301997
2. Navin PJ, Venkatesh SK, Hepatocellular carcinoma: State of the art imaging and recent advances: J Clin Transl Hepatol, 2019; 7; 72-85, pmid: 30944823
3. Sasaki R, Kanda T, Yokosuka O, Exosomes and hepatocellular carcinoma: From bench to bedside: Int J Mol Sci, 2019; 20(6) pii: E1406
4. Tsuchiya A, Ogawa M, Watanabe T, Diverse perspectives to address for the future treatment of heterogeneous hepatocellular carcinoma: Heliyon, 2019; 5; e01325, pmid: 30911692
5. Sadri Nahand J, Bokharaei-Salim F, Salmaninejad A, MicroRNAs: Key players in virus-associated hepatocellular carcinoma: J Cell Physiol, 2019; 234(8); 12188-225, pmid: 30536673
6. Song Y, Wang F, Huang Q, MicroRNAs contribute to hepatocellular carcinoma: Mini Rev Med Chem, 2015; 15; 459-66, pmid: 25807945
7. Wen Y, Han J, Chen J, Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma: Int J Cancer, 2015; 137; 1679-90, pmid: 25845839
8. Acunzo M, Romano G, Wernicke D, MicroRNA and cancer – a brief overview: Adv Biolog Regul, 2015; 57; 1-9
9. Flatmark K, Hoye E, Fromm B, MicroRNAs as cancer biomarkers: Scand J Clin Lab Invest Suppl, 2016; 245; S80-83, pmid: 27542003
10. Tutar L, Ozgur A, Tutar Y, Involvement of miRNAs and pseudogenes in cancer: Methods Mol Biol, 2018; 1699; 45-66, pmid: 29086367
11. Tang H, Zhao H, Yu ZY, MicroRNA-194 inhibits cell invasion and migration in hepatocellular carcinoma through PRC1-mediated inhibition of Wnt/beta-catenin signaling pathway: Dig Liver Dis, 2019; 51(9); 1314-22, pmid: 30948333
12. Du H, Xu Q, Xiao S, MicroRNA-424-5p acts as a potential biomarker and inhibits proliferation and invasion in hepatocellular carcinoma by targeting TRIM29: Life Sci, 2019; 224; 1-11, pmid: 30876939
13. Aslan C, Maralbashi S, Salari F, Tumor-derived exosomes: Implication in angiogenesis and antiangiogenesis cancer therapy: J Cell Physiol, 2019; 234(10); 16885-93, pmid: 30793767
14. Chen BY, Sung CW, Chen C, Advances in exosomes technology: Clin Chim Acta, 2019; 493; 14-19, pmid: 30797770
15. Kohama I, Kosaka N, Chikuda H, An insight into the roles of microRNAs and exosomes in sarcoma: Cancers (Basel), 2019; 11(3) pii: E428
16. Mashouri L, Yousefi H, Aref AR, Exosomes: Composition, biogenesis, and mechanisms in cancer metastasis and drug resistance: Mol Cancer, 2019; 18; 75, pmid: 30940145
17. Wu M, Wang G, Hu W, Emerging roles and therapeutic value of exosomes in cancer metastasis: Mol Cancer, 2019; 18; 53, pmid: 30925925
18. Xie Y, Dang W, Zhang S, The role of exosomal noncoding RNAs in cancer: Mol Cancer, 2019; 18; 37, pmid: 30849983
19. Fu Q, Zhang Q, Lou Y, Primary tumor-derived exosomes facilitate metastasis by regulating adhesion of circulating tumor cells via SMAD3 in liver cancer: Oncogene, 2018; 37; 6105-18, pmid: 29991801
20. Liu WH, Yeh SH, Lu CC, MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells: Gastroenterology, 2009; 136; 683-93, pmid: 19027010
21. Miller IV, Grunewald TG, Tumour-derived exosomes: Tiny envelopes for big stories: Biol Cell, 2015; 107; 287-305, pmid: 25923825
22. Greening DW, Gopal SK, Xu R, Exosomes and their roles in immune regulation and cancer: Semin Cell Dev Biol, 2015; 40; 72-81, pmid: 25724562
23. Fu Y, Liu X, Zhou N, MicroRNA-200b stimulates tumour growth in TGFBR2-null colorectal cancers by negatively regulating p27/kip1: J Cell Physiol, 2014; 229; 772-82, pmid: 24151081
24. Fu Y, Zhang L, Zhang F, Exosome-mediated miR-146a transfer suppresses type I interferon response and facilitates EV71 infection: PLoS Pathog, 2017; 13; e1006611, pmid: 28910400
25. Alvarez-Garcia V, Tawil Y, Wise HM, Mechanisms of PTEN loss in cancer: It’s all about diversity: Semin Cancer Biol, 2019 [Epub ahead of print]
26. Bazzichetto C, Conciatori F, Pallocca M, PTEN as a prognostic/predictive biomarker in cancer: an unfulfilled promise?: Cancers, 2019; 11(4); E435, pmid: 30925702
27. Corti F, Nichetti F, Raimondi A, Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives: Cancer Treat Rev, 2019; 72; 45-55, pmid: 30476750
28. Hu M, Zhu S, Xiong S, MicroRNAs and the PTEN/PI3K/Akt pathway in gastric cancer (review): Oncol Rep, 2019; 41; 1439-54, pmid: 30628706
29. Fu X, Wen H, Jing L, MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway: Cancer Sci, 2017; 108; 620-31, pmid: 28132399
30. Noorolyai S, Shajari N, Baghbani E, The relation between PI3K/AKT signalling pathway and cancer: Gene, 2019; 698; 120-28, pmid: 30849534
31. Hartke J, Johnson M, Ghabril M, The diagnosis and treatment of hepatocellular carcinoma: Semin Diagn Pathol, 2017; 34; 153-59, pmid: 28108047
32. Ruivo CF, Adem B, Silva M, The biology of cancer exosomes: Insights and new perspectives: Cancer Res, 2017; 77; 6480-88, pmid: 29162616
33. Bondada MS, Yao Y, Nair V, Multifunctional miR-155 pathway in avian oncogenic virus-induced neoplastic diseases: Noncoding RNA, 2019; 5 pii: E24
34. Eissa MG, Artlett CM, The microRNA miR-155 is essential in fibrosis: Noncoding RNA, 2019; 5 pii: E23
35. Tam W, Ben-Yehuda D, Hayward WS, Bic, a novel gene activated by proviral insertions in avian leukosis virus-induced lymphomas, is likely to function through its noncoding RNA: Mol Cell Biol, 1997; 17; 1490-502, pmid: 9032277
36. Wang B, Majumder S, Nuovo G, Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice: Hepatology, 2009; 50; 1152-61, pmid: 19711427
37. Han ZB, Chen HY, Fan JW, Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation: J Cancer Res Clin Oncol, 2012; 138; 153-61, pmid: 22071603
38. Ji J, Zheng X, Forgues M, Identification of microRNAs specific for epithelial cell adhesion molecule-positive tumor cells in hepatocellular carcinoma: Hepatology, 2015; 62; 829-40, pmid: 25953724
39. Eissing M, Ripken L, Schreibelt G, PTEN hamartoma tumor syndrome and immune dysregulation: Transl Oncol, 2019; 12; 361-67, pmid: 30504085
40. Li K, Li GD, Sun LY, PTEN and SHIP: impact on lymphatic metastasis in breast cancer: J Cancer Res Ther, 2018; 14; S937-41, pmid: 30539826
41. Mei W, Lin X, Kapoor A, The contributions of prostate cancer stem cells in prostate cancer initiation and metastasis: Cancers (Basel), 2019; 11 pii: E434
42. Noorolyai S, Mokhtarzadeh A, Baghbani E, The role of microRNAs involved in PI3-kinase signaling pathway in colorectal cancer: J Cell Physiol, 2019; 234; 5664-73, pmid: 30488557
43. Raffone A, Travaglino A, Saccone G, Loss of PTEN expression as diagnostic marker of endometrial precancer: A systematic review and meta-analysis: Acta Obstet Gynecol Scand, 2019; 98; 275-86, pmid: 30511743
44. Yehia L, Ngeow J, Eng C, PTEN-opathies: from biological insights to evidence-based precision medicine: J Clin Invest, 2019; 129; 452-64, pmid: 30614812
45. Wang Y, Zhang C, Zhang P, Serum exosomal microRNAs combined with alpha-fetoprotein as diagnostic markers of hepatocellular carcinoma: Cancer Med, 2018; 7; 1670-79, pmid: 29573235
46. Fornari F, Ferracin M, Trere D, Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, identify cirrhotic patients with HCC: PLoS One, 2015; 10; e0141448, pmid: 26509672
47. Lin XJ, Fang JH, Yang XJ: Mol Ther Nucleic Acids, 2018; 11; 243-52, pmid: 29858059
48. Matsuura Y, Wada H, Eguchi H, Exosomal miR-155 derived from hepatocellular carcinoma cells under hypoxia promotes angiogenesis in endothelial cells: Dig Dis Sci, 2019; 64; 792-802, pmid: 30465177
Most Viewed Current Articles
13 Apr 2020 : Original article 19,586
Outcome of 24 Weeks of Combined Schroth and Pilates Exercises on Cobb Angle, Angle of Trunk Rotation, Chest...DOI :10.12659/MSMBR.920449
Med Sci Monit Basic Res 2020; 26:e920449
20 Apr 2018 : Original article 17,466
Brain Training Games Enhance Cognitive Function in Healthy SubjectsDOI :10.12659/MSMBR.909022
Med Sci Monit Basic Res 2018; 24:63-69
23 Jul 2016 : Review article 10,353
Cardiac Hypertrophy: An Introduction to Molecular and Cellular BasisDOI :10.12659/MSMBR.900437
Med Sci Monit Basic Res 2016; 22:75-79
10 Aug 2020 : Clinical Research 9,788
Effects of Cognitive Task Training on Dynamic Balance and Gait of Patients with Stroke: A Preliminary Rando...DOI :10.12659/MSMBR.925264
Med Sci Monit Basic Res 2020; 26:e925264






